Applications

1528 – Somatic tumour gene testing for the diagnosis of renal cell carcinoma, hydatidiform moles, granulosa cell ovarian tumour, salivary gland tumours, and secretory carcinoma of the breast

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type -
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

New MBS item

Service or technology in this application

Characterisation of VHL, TP53, RB1 status, TFE3 / Xp11.1 translocation and detection of chromosome 3 (chr3) monosomy for the diagnosis of RCC; characterisation of ploidy status for the diagnosis and classification of patients with hydatidiform moles; classification of mutation in FOXL2 (402C>G) for the diagnosis of granulosa cell ovarian tumour; detection of somatic gene rearrangements for the diagnosis of salivary gland tumours including mammary analogue secretory carcinoma, hyalinising clear cell carcinoma, mucoepidermoid and NUT midline carcinomas; and characterisation of somatic tumour gene rearrangements for the diagnosis of secretory carcinoma of the breast.

Type: Investigative

Medical condition this application addresses

Renal cell carcinoma (RCC); hydatidiform moles; granulosa cell ovarian tumour; salivary gland tumours; and secretory carcinoma of the breast.

Application documents

Application form

Consultation survey

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: 12 to 13 April 2018
  • ESC meeting: -
  • MSAC meeting: 
    • 1 to 2 August 2019
    • 28 to 29 November 2019